PDCD1 and neoplasm: Furthermore, increasing tumor mutation burden, usually defined as the number of nonsynonymous mutations per megabase of sequenced DNA, is also a predictive biomarker for better response to programmed cell death 1 (PD-1) blockade and improved clinical outcomes [18, 19].